INSM — Insmed Incorporated price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $121.16
- YTD price return
- -30.38%
- YTD total return
- -30.38%
- Market cap
- 26.6B
- Enterprise value
- 26B
- Shares outstanding
- 219.4M
- 52W low
- $90.39
- 52W high
- $212.75
- From 52W high
- -43.05%
- From 52W low
- +34.04%
- 52W range
- 25%$90.39–$213
- Beta
- 0.85
Volume
- Rel volume
- 0.43×
- 30D volume
- 3.6M
- 30D $ vol
- 375.4M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$3.7M
- Insider net 1Y
- −$122.8M
Form 4 transactions by trade date, as filed; latest on file 2026-09-09.
Fundamentals
- Sales (ttm)
- 1.5B
- Sales/share
- $6.93
- EPS (ttm)
- -$2.80
- FCF (ttm)
- -627.6M
- FCF/share
- -$2.86
- Book value/share
- $3.31
- Net margin
- -39.85%
- ROE
- -83.39%
- ROA
- -27.21%
- Debt / equity
- 0.75×
- Current ratio
- 2.86
Growth (CAGR, ttm) · 10Y
- Sales
- +240.25%+75.55%+54.31%n/a
- Shares
- +2.87%+15.31%+13.13%+13.49%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +230.77%+52.24%+36.39%n/a
- Book value/share
- -25.35%n/a-4.94%-0.61%
- Price
- -36.57%+71.76%+30.61%+23.68%
- Total return
- -36.57%+71.76%+30.61%+23.68%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -43.3×
- Fwd P/E
- 172.6×
- P/S (ttm)
- 17.5×
- P/B (mrq)
- 36.6×
- EV/Sales (ttm)
- 17.1×
- FCF yield (ttm)
- -2.36%
- Buyback yield (realized, 1y)
- -2.87%
- Shareholder yield (realized, 1y)
- -2.87%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/S
- 44th
- P/B
- 81st
Bar = where today’s multiple sits in INSM’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-13#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m10Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m10Y n/mYoY n/mTTM: operating cash flow −$595.6M, capex −$32M
Q3 2026: operating cash flow −$36.5M, capex −$5.6M
Shares (diluted)
5Y +103.9%10Y +239.4%YoY +3.3%Net income
5Y n/m10Y n/mYoY n/mAbout Insmed#
Data provided bySource: Twelve DataInsmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory conditions. The company’s pipeline emphasizes innovative approaches such as oral therapies and inhaled medicines designed to address difficult-to-treat respiratory disorders. Insmed also conducts research across multiple scientific platforms, including protein engineering and other advanced drug-development technologies. Headquartered in Bridgewater, New Jersey, Insmed serves patients and healthcare providers in the United States, Europe, Japan, and other international markets, positioning itself as a specialist in rare-disease and specialty respiratory treatment.
Bridgewater, NJ·1,664 employees·Biotechnology·insmed.com·As of Oct 28, 2026
Recent filings#
- Oct 29Earnings · Earnings release — EPS −$0.46 vs −$0.34 est. (−35.3%); revenue $524.4M (+268% y/y) 15.1%
- Sep 9Insider sale · Brennan David R (Director) sold 25,000 shares for $3.1M at $124.00
- Aug 17Insider sale · SHAROKY MELVIN MD (Director) sold 5,000 shares for $638K at $127.53
- Aug 10Insider sale · Adsett Roger (Chief Operating Officer) sold 239,850 shares for $32.0M at $133.27
- Aug 6Earnings · Earnings release — EPS −$0.52 vs −$0.69 est. (+24.6%); revenue $425.5M (+296% y/y) 33.9%
ETFs holding INSM#
27 of the 193 ETFs ChartRow carries live hold INSM. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 1.8% |
| XBI | SPDR S&P Biotech ETF | 1.1% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.6% |
| VHT | Vanguard Health Care ETF | 0.4% |
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| VXF | Vanguard Extended Market ETF | 0.3% |
| VOT | Vanguard Mid-Cap Growth ETF | 0.3% |
| IWR | iShares Russell Midcap ETF | 0.2% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +23.75% | +1.14% |
| JNJ | Johnson & Johnson | +14.94% | +0.79% |
| ABBV | AbbVie Inc. | +7.53% | +0.20% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +7.86% | +0.58% |
| MRK | Merck & Co. Inc. | +4.07% | +0.55% |
| NVS | Novartis AG | +12.70% | +0.16% |
| TMO | Thermo Fisher Scientific Inc. | +5.61% | +0.11% |
| AMGN | Amgen Inc. | +12.80% | -0.30% |
